Home › Trials › NCT06500884

Evaluating treatments to prevent taste changes from talquetamab in multiple myeloma patients

A Phase 2, Open-label, Randomized Study to Evaluate GPRC5D-related Oral Events

Phase 2 Interventional Janssen Research & Development, LLC · NCT06500884

This study is testing different treatments to see if they can help multiple myeloma patients avoid or lessen taste changes caused by the drug talquetamab.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment210 (estimated)
Ages18 Years and up
SexAll
SponsorJanssen Research & Development, LLC Industry-sponsored
Drugs / interventionstalquetamab
Locations38 sites (San Francisco, California and 37 other locations)
Trial IDNCT06500884 on ClinicalTrials.gov

What this trial studies

This study aims to identify preventive treatments that can reduce the occurrence, severity, and duration of taste changes (dysgeusia) associated with talquetamab in patients with relapse or refractory multiple myeloma. Participants will receive various prophylactic treatments during the preventive phase to assess their effectiveness. The study will also characterize the signs and symptoms related to talquetamab-induced taste changes. It is designed as a Phase 2 interventional trial to gather data on these preventive measures.

Who should consider this trial

Good fit: Ideal candidates include adults with relapse or refractory multiple myeloma who have previously been treated with multiple classes of therapies and have a stable performance status.

Not a fit: Patients who have contraindications to talquetamab or those with severe neurological conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could significantly improve the quality of life for multiple myeloma patients undergoing treatment with talquetamab by minimizing unpleasant taste changes.

How similar studies have performed: While there is limited information on similar studies specifically targeting talquetamab-related taste changes, the approach of preventive treatment in oncology has shown promise in other contexts.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Multiple myeloma (MM) according to IMWG diagnostic criteria
* Were triple-class exposed (received prior treatment with a PI, an IMiD, and anti CD38 mAb)
* Documented evidence of progressive disease based on investigator's determination of response by IMWG criteria on or after their last regimen
* Have an Eastern Cooperative Oncology Group-performance status (ECOG-PS) of 0 or 1 at screening. Participants with ECOG-PS 2 or 3 are eligible for the study if the ECOG-PS score is related to stable physical limitations (e.g., wheelchair-bound due to prior spinal cord injury) and not related to multiple myeloma or associated therapy
* Be willing and able to adhere to the lifestyle restrictions specified in the protocol

Exclusion Criteria:

* Contraindications or life-threatening known allergies, hypersensitivity, or intolerance to any study drug or its excipients
* Stroke, transient ischemic attack, or seizure within 6 months prior to screening
* Any of the following within 6 months prior to the first dose of study treatment: severe or unstable angina, myocardial infarction; major thromboembolytic event (e.g., pulmonary embolism, cerebrovascular accident), clinically significant ventricular arrythmia or heart failure New York Heart Association functional classification Class III or IV. Uncomplicated deep vein thrombosis is not considered exclusionary
* Major surgery or had significant traumatic injury within 2 weeks prior to the start of administration of study treatment, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to be treated in the study or within 2 weeks after administration of the last dose of study treatment
* A WETT score indicating severe dysgeusia at screening and confirmed prior to randomization. Also unresolved/severe dysgeusia referred by the participant or a finding in the physical examination/oral cavity inspection. Some examples include leukoplakia, prior mouth cancers, extensive dental caries, severe periodontitis, active oral infections, candidiasis, parotic gland removal, or radiotherapy with resultant xerostomia

Where this trial is running

San Francisco, California and 37 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Multiple Myeloma
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.